<?xml version="1.0" encoding="UTF-8"?>
<p id="para0007">The regulations governing the manufacture and application of biological products of human origin, and especially those obtained from cells, are complex 
 <xref rid="bib0015" ref-type="bibr">[15]</xref>, 
 <xref rid="bib0016" ref-type="bibr">[16]</xref>, 
 <xref rid="bib0017" ref-type="bibr">[17]</xref> and not always well known by the professionals who prescribe or administer these treatments. In brief, cell- and tissue-based products subjected to substantial manipulation or not intended to be used for the same essential function are classified as advanced therapy medicinal products (ATMPs) in the European Union (EU). The European Regulation 1394/2007 on ATMPs [
 <xref rid="bib0018" ref-type="bibr">18</xref>], mandatory for all EU countries, establishes a centralized marketing authorization procedure for these medicinal products when they are intended to be placed on the market.
</p>
